Please assess the completion status of the following clinical trial:

Trial Title: An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatients 18 years of age or older~* Male or female patients are eligible~* For newly diagnosed/untreated patients with essential hypertension defined as msDBP ≥ 90 and \< 110 mmHg at Visit 1 and Visit 4~* For previously treated patients with essential hypertension defined as msDBP ≥ 90 and \< 110 mmHg after 2 to 4 weeks of washout (Visit 4)~Exclusion Criteria:~* Severe hypertension~* History or evidence of a secondary form of hypertension~* History of Hypertensive encephalopathy or cerebrovascular accident.~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aliskiren/Amlodipine (Type: EXPERIMENTAL): None
- Aliskiren/Amlodipine/HCTZ (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).